Google ScholarScopusUCL IrisORCiD

Book chapters 6
Journal articles 83
Total citations 6631
h-index 35
i10-index 56

Last updated May 2019

Book chapters

  1. Biofluid Biomarkers for Huntington’s Disease
    F Rodrigues, L Byrne & E Wild
    In Methods in Molecular Biology: Huntington’s Disease
    eds. Precious, Rosser & Dunnett. Springer, 2018.
  2. Premanifest and Early Huntington’s Disease
    E Wild & S Tabrizi.
    In Huntington’s Disease (Oxford Monographs on Medical Genetics), 3rd ed. Eds G Bates, L Jones & S Tabrizi. Oxford University Press, 2015.
  3. Huntington’s Disease & Other Choreas
    S Haider, E Wild & S Tabrizi.
    In Neurodegeneration, ed. A Schapira. Wiley, 2014.
  4. Huntington’s disease look-alike syndromes
    E Wild & S Tabrizi.
    In Oxford Textbooks in Clinical Neurology: Movement Disorders (2nd edition), ed. D Burn. Oxford University Press, 2013.
  5. Huntington’s Disease
    S Tabrizi & E Wild
    In Neurogenetics: A Guide for Clinicians (2nd edition), ed. N Wood. Cambridge University Press, 2012
  6. Huntington’s Disease and Dementia
    E Wild, N Hobbs & S Henley.
    In Neuroimaging in Dementia (1st edition), ed. F Barkhof, J Valk & N Fox. Springer-Verlag, 2011

PhD Thesis

Identification and evaluation of biomarkers for Huntington’s disease, 2009. University College London.

Peer-reviewed journal articles

  1. Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM.
    Targeting Huntingtin Expression in Patients with Huntington’s Disease.

    N Engl J Med. 2019 May 6.
  2. Anderson DG, Ferreira-Correia A, Rodrigues FB, Aziz NA, Carr J, Wild EJ, Margolis RL, Krause A.
    Comparison of the Huntington’s Disease like 2 and Huntington’s Disease Clinical Phenotypes.

    Mov Disord Clin Pract. 2019 Mar 12;6(4):302-311.
  3. Zeun P, Scahill RI, Tabrizi SJ, Wild EJ.
    Fluid and imaging biomarkers for Huntington’s disease.

    Mol Cell Neurosci. 2019 Feb 23.
  4. Rodrigues FB, Byrne LM, De Vita E, Johnson EB, Hobbs NZ, Thornton JS, Scahill RI, Wild EJ.
    Cerebrospinal fluid flow dynamics in Huntington’s disease evaluated by phase contrast MRI.

    Eur J Neurosci. 2019 Jan 28.
  5. Rodrigues FB, Quinn L, Wild EJ.
    Huntington’s Disease Clinical Trials Corner: January 2019.

    J Huntingtons Dis. 2019;8(1):115-125.
  6. Byrne LM, Rodrigues FB, Johnson EB, Wijeratne PA, De Vita E, Alexander DC, Palermo G, Czech C, Schobel S, Scahill RI, Heslegrave A, Zetterberg H, Wild EJ.
    Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease.

    Sci Transl Med. 2018 Sep 12;10(458).
  7. Koriath C, Kenny J, Adamson G, Druyeh R, Taylor W, Beck J, Quinn L, Mok TH, Dimitriadis A, Norsworthy P, Bass N, Carter J, Walker Z, Kipps C, Coulthard E, Polke JM, Bernal-Quiros M, Denning N, Thomas R, Raybould R, Williams J, Mummery CJ, Wild EJ, Houlden H, Tabrizi SJ, Rossor MN, Hummerich H, Warren JD, Rowe JB, Rohrer JD, Schott JM, Fox NC, Collinge J, Mead S.
    Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series.

    Mol Psychiatry. 2018 Oct 2.
  8. Oosterloo M, Bijlsma EK, van Kuijk SM, Minkels F, de Die-Smulders CE; REGISTRY Investigators of the European Huntington’s Disease Network; Registry Steering committee; Language coordinators; EHDN’s associate site in Singapore.
    Clinical and genetic characteristics of late-onset Huntington’s disease.

    Parkinsonism Relat Disord. 2019 Apr;61:101-105.
  9. Rodrigues FB, Ferreira JJ, Wild EJ.
    Physician perception versus true efficacy of tetrabenazine for Huntington’s disease.

    Curr Med Res Opin. 2018 Sep;34(9):1537-1538.
  10. Barkhuizen M, Rodrigues FB, Anderson DG, Winkens B; REGISTRY Investigators of the European Huntington’s Disease Network, Wild EJ, Kramer BW, Gavilanes AWD.
    Perinatal insults and neurodevelopmental disorders may impact Huntington’s disease age of diagnosis.

    Parkinsonism Relat Disord. 2018 Oct;55:55-60.
  11. Byrne LM, Rodrigues FB, Johnson EB, De Vita E, Blennow K, Scahill R, Zetterberg H, Heslegrave A, Wild EJ.
    Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease.

    Sci Rep. 2018 Mar 9;8(1):4260.
  12. Johnson EB, Byrne LM, Gregory S, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RA, Zetterberg H, Tabrizi SJ, Scahill RI, Wild EJ; TRACK-HD Study Group.
    Neurofilament light protein in blood predicts regional atrophy in Huntington disease.

    Neurology. 2018 Feb 20;90(8):e717-e723.
  13. Rodrigues FB, Wild EJ.
    Huntington’s Disease Clinical Trials Corner: February 2018

    J Huntingtons Dis. 2018;7(1):89-98.
  14. Hensman Moss DJ, Robertson N, Farmer R, Scahill RI, Haider S, Tessari MA, Flynn G, Fischer DF, Wild EJ, Macdonald D, Tabrizi SJ.
    Quantification of huntingtin protein species in Huntington’s disease patient leukocytes using optimised electrochemiluminescence immunoassays.

    PLoS One. 2017 Dec 22;12(12):e0189891.
  15. Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ.
    Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease”.

    J Clin Mov Disord. 2017 Nov 22;4:19.
  16. Fodale V, Boggio R, Daldin M, Cariulo C, Spiezia MC, Byrne LM, Leavitt BR, Wild EJ, Macdonald D, Weiss A, Bresciani A.
    Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay.

    J Huntingtons Dis. 2017;6(4):349-361.
  17. Wild EJ, Tabrizi SJ.
    Therapies targeting DNA and RNA in Huntington’s disease.

    Lancet Neurol. 2017 Oct;16(10):837-847.
  18. Soylu-Kucharz R, Sandelius Å, Sjögren M, Blennow K, Wild EJ, Zetterberg H, Björkqvist M.
    Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice.

    Sci Rep. 2017 Oct 26;7(1):14114.
  19. Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC, Scahill RI, Tabrizi SJ, Zetterberg H, Langbehn D, Wild EJ.
    Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis.

    Lancet Neurol. 2017 Aug;16(8):601-609.
  20. Rodrigues FB, Wild EJ.
    Clinical Trials Corner: September 2017.

    J Huntingtons Dis. 2017;6(3):255-263.
  21. Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ.
    Tetrabenazine Versus Deutetrabenazine for Huntington’s Disease: Twins or Distant Cousins?

    Mov Disord Clin Pract. 2017 Jul-Aug;4(4):582-585.
  22. Salanio DM, Taylor R, Stanton JED, Wild EJ.
    Ghost Pills: A Case Report.

    Ann Intern Med. 2017 Apr 18;166(8):609.
  23. Rodrigues FB, Byrne LM, McColgan P, Robertson N, Tabrizi SJ, Zetterberg H, Wild EJ.
    Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington’s Disease.

    PLoS One. 2016 Sep 22;11(9):e0163479.
  24. Wexler A, Wild EJ, Tabrizi SJ.
    George Huntington: a legacy of inquiry, empathy and hope.

    Brain. 2016 Aug;139(Pt 8):2326-33.
  25. Wild EJ.
    Huntington’s Disease: The Most Curable Incurable Brain Disorder?

    EBioMedicine. 2016 Jun;8:3-4.
  26. Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C; European HD Network.
    Clinical manifestations of intermediate allele carriers in Huntington disease.

    Neurology. 2016 Aug 9;87(6):571-8.
  27. Rodrigues FB, Byrne L, McColgan P, Robertson N, Tabrizi SJ, Leavitt BR, Zetterberg H, Wild EJ.
    Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington’s disease.

    J Neurochem. 2016 Oct;139(1):22-5.
  28. Rodrigues FB, Wild EJ.
    Psychogenic non-epileptic seizures in early Huntington’s disease.

    Pract Neurol. 2016 Dec;16(6):452-454.
  29. Byrne LM, Wild EJ.
    Cerebrospinal Fluid Biomarkers for Huntington’s Disease.

    J Huntingtons Dis. 2016;5(1):1-13.
  30. Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JR, Zetterberg H, Leavitt BR, Kuhn R, Tabrizi SJ, Macdonald D, Weiss A.
    Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients.

    J Clin Invest. 2015 May;125(5):1979-86.
  31. Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ, Tabrizi SJ.
    Huntington disease.

    Nat Rev Dis Primers. 2015 Apr 23;1:15005.
  32. Wild EJ, Tabrizi SJ.
    Targets for future clinical trials in Huntington’s disease: what’s in the pipeline?

    Mov Disord. 2014 Sep 15;29(11):1434-45.
  33. Gregory S, Scahill RI, Seunarine KK, Stopford C, Zhang H, Zhang J, Orth M, Durr A, Roos RA, Langbehn DR, Long JD, Johnson H, Rees G, Tabrizi SJ, Craufurd D,; Track-HD Investigators.
    Neuropsychiatry and White Matter Microstructure in Huntington’s Disease.

    J Huntingtons Dis. 2015;4(3):239-49.
  34. Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, Reilmann R, Unschuld PG, Wexler A, Margolis RL, Tabrizi SJ.
    Huntington disease: natural history, biomarkers and prospects for therapeutics.

    Nat Rev Neurol. 2014 Apr;10(4):204-16.
  35. Hensman Moss DJ, Poulter M, Beck J, Hehir J, Polke JM, Campbell T, Adamson G, Mudanohwo E, McColgan P, Haworth A, Wild EJ, Sweeney MG, Houlden H, Mead S, Tabrizi SJ.
    C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies.

    Neurology. 2014 Jan 28;82(4):292-9.
  36. Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ; REGISTRY investigators of the European Huntington’s Disease Network.
    Suicidal ideation in a European Huntington’s disease population.

    J Affect Disord. 2013 Oct;151(1):248-58.
  37. Metzger S, Walter C, Riess O, Roos RA, Nielsen JE, Craufurd D; REGISTRY Investigators of the European Huntington’s Disease Network, Nguyen HP.
    The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients.

    PLoS One. 2013 Jul 22;8(7):e68951.
  38. Träger U, Magnusson A, Lahiri Swales N, Wild E, North J, Lowdell M, Björkqvist M.
    JAK/STAT Signalling in Huntington’s Disease Immune Cells.

    PLoS Curr. 2013 Dec 13;5.
  39. Vittori A, Orth M, Roos RA, Outeiro TF, Giorgini F, Hollox EJ; REGISTRY investigators of the European Huntington’s Disease Network.
    β-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington’s Disease.

    J Huntingtons Dis. 2013 Mar 27;2(1):107-124.
  40. Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR; TRACK-HD Investigators.
    Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data.

    Lancet Neurol. 2013 Jul;12(7):637-49.
  41. Crawford HE, Hobbs NZ, Keogh R, Langbehn DR, Frost C, Johnson H, Landwehrmeyer B, Reilmann R, Craufurd D, Stout JC, Durr A, Leavitt BR, Roos RA, Tabrizi SJ, Scahill RI; TRACK-HD Investigators.
    Corpus callosal atrophy in premanifest and early Huntington’s disease.

    J Huntingtons Dis. 2013;2(4):517-26.
  42. Scahill RI, Wild EJ, Tabrizi SJ.
    Biomarkers for Huntington’s disease: an update.

    Expert Opin Med Diagn. 2012 Sep;6(5):371-5.
  43. Hobbs NZ, Barnes J, Frost C, Henley SM, Wild EJ, Macdonald K, Barker RA, Scahill RI, Fox NC, Tabrizi SJ.
    Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study.

    AJNR Am J Neuroradiol. 2010 Jun;31(6):1036-41.
  44. Weiss A, Träger U, Wild EJ, Grueninger S, Farmer R, Landles C, Scahill RI, Lahiri N, Haider S, Macdonald D, Frost C, Bates GP, Bilbe G, Kuhn R, Andre R, Tabrizi SJ.
    Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression.

    J Clin Invest. 2012 Oct;122(10):3731-6.
  45. Stout JC, Jones R, Labuschagne I, O’Regan AM, Say MJ, Dumas EM, Queller S, Justo D, Santos RD, Coleman A, Hart EP, Dürr A, Leavitt BR, Roos RA, Langbehn DR, Tabrizi SJ, Frost C.
    Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington’s disease.

    J Neurol Neurosurg Psychiatry. 2012 Jul;83(7):687-94.
  46. Andre R, Wild EJ, Tabrizi SJ.
    Huntington’s disease: fighting on many fronts.

    Brain. 2012 Apr;135(Pt 4):998-1001.
  47. Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS; PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB; REGISTRY study of the European Huntington’s Disease Network, Myers RH; HD-MAPS Study Group, MacDonald ME, Gusella JF; COHORT study of the HSG.
    CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.

    Neurology. 2012 Mar 6;78(10):690-5.
  48. Quarrell OW, Handley O, O’Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I, Bauer P, Kline M, Landwehrmeyer GB; European Huntington’s Disease Network.
    Discrepancies in reporting the CAG repeat lengths for Huntington’s disease.

    Eur J Hum Genet. 2012 Jan;20(1):20-6.
  49. Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR; TRACK-HD investigators.
    Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data.

    Lancet Neurol. 2012 Jan;11(1):42-53.
  50. Orth M; European Huntington’s Disease Network, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB.
    Observing Huntington’s disease: the European Huntington’s Disease Network’s REGISTRY.

    J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1409-12.
  51. Wild EJ, Carroll JB.
    HDBuzz: empowering patients through accessible education.

    Trends Mol Med. 2012 Jan;18(1):1-3.
  52. Henley SM, Ridgway GR, Scahill RI, Klöppel S, Tabrizi SJ, Fox NC, Kassubek J; EHDN Imaging Working Group.
    Pitfalls in the use of voxel-based morphometry as a biomarker: examples from huntington disease.

    AJNR Am J Neuroradiol. 2010 Apr;31(4):711-9.
  53. Zuccato C, Marullo M, Vitali B, Tarditi A, Mariotti C, Valenza M, Lahiri N, Wild EJ, Sassone J, Ciammola A, Bachoud-Lèvi AC, Tabrizi SJ, Di Donato S, Cattaneo E.
    Brain-derived neurotrophic factor in patients with Huntington’s disease.

    PLoS One. 2011;6(8):e22966.
  54. Saft C, Epplen JT, Wieczorek S, Landwehrmeyer GB, Roos RA, de Yebenes JG, Dose M, Tabrizi SJ, Craufurd D; REGISTRY Investigators of the European Huntington’s Disease Network, Arning L.
    NMDA receptor gene variations as modifiers in Huntington disease: a replication study.

    PLoS Curr. 2011 Oct 4;3:RRN1247.
  55. Wild E, Magnusson A, Lahiri N, Krus U, Orth M, Tabrizi SJ, Björkqvist M.
    Abnormal peripheral chemokine profile in Huntington’s disease.

    PLoS Curr. 2011 Apr 13;3:RRN1231.
  56. Munsie L, Caron N, Atwal RS, Marsden I, Wild EJ, Bamburg JR, Tabrizi SJ, Truant R.
    Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease.

    Hum Mol Genet. 2011 May 15;20(10):1937-51.
  57. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC; TRACK-HD Investigators.
    Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis.

    Lancet Neurol. 2011 Jan;10(1):31-42.
  58. Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB; Investigators of the European Huntington’s Disease Network.
    Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY.

    Version 2. PLoS Curr. 2010 Sep 28 [revised 2011 Apr 13];2:RRN1184.
  59. Wild EJ, Henley SM, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ.
    Rate and acceleration of whole-brain atrophy in premanifest and early Huntington’s disease.

    Mov Disord. 2010 May 15;25(7):888-95.
  60. Hobbs NZ, Henley SM, Ridgway GR, Wild EJ, Barker RA, Scahill RI, Barnes J, Fox NC, Tabrizi SJ.
    The progression of regional atrophy in premanifest and early Huntington’s disease: a longitudinal voxel-based morphometry study.

    J Neurol Neurosurg Psychiatry. 2010 Jul;81(7):756-63.
  61. Aziz NA, Jurgens CK, Landwehrmeyer GB; EHDN Registry Study Group, van Roon-Mom WM, van Ommen GJ, Stijnen T, Roos RA.
    Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease.

    Neurology. 2009 Oct 20;73(16):1280-5.
  62. Wild EJ, Fox NC.
    Serial volumetric MRI in Parkinsonian disorders.

    Mov Disord. 2009;24 Suppl 2:S691-8.
  63. Björkqvist M, Wild EJ, Tabrizi SJ.
    Harnessing immune alterations in neurodegenerative diseases.

    Neuron. 2009 Oct 15;64(1):21-4.
  64. Hobbs NZ, Henley SM, Wild EJ, Leung KK, Frost C, Barker RA, Scahill RI, Barnes J, Tabrizi SJ, Fox NC.
    Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington’s disease.

    Neuroimage. 2009 Oct 1;47(4):1659-65.
  65. Henley SM, Wild EJ, Hobbs NZ, Scahill RI, Ridgway GR, Macmanus DG, Barker RA, Fox NC, Tabrizi SJ.
    Relationship between CAG repeat length and brain volume in premanifest and early Huntington’s disease.

    J Neurol. 2009 Feb;256(2):203-12.
  66. Henley SM, Wild EJ, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ.
    Whole-brain atrophy as a measure of progression in premanifest and early Huntington’s disease.

    Mov Disord. 2009 Apr 30;24(6):932-6.
  67. Wild E, Björkqvist M, Tabrizi SJ.
    Immune markers for Huntington’s disease?

    Expert Rev Neurother. 2008 Dec;8(12):1779-81.
  68. Leoni V, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, Henley SM, Hobbs NZ, Mandelli ML, Grisoli M, Björkhem I, Cattaneo E, Di Donato S.
    Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington’s disease.

    Brain. 2008 Nov;131(Pt 11):2851-9.
  69. Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, Möller T, Tabrizi SJ.
    A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease.

    J Exp Med. 2008 Aug 4;205(8):1869-77.
  70. Arnulf I, Nielsen J, Lohmann E, Schiefer J, Wild E, Jennum P, Konofal E, Walker M, Oudiette D, Tabrizi S, Durr A.
    Rapid eye movement sleep disturbances in Huntington disease.

    Arch Neurol. 2008 Apr;65(4):482-8.
  71. Henley SM, Wild EJ, Hobbs NZ, Warren JD, Frost C, Scahill RI, Ridgway GR, MacManus DG, Barker RA, Fox NC, Tabrizi SJ.
    Defective emotion recognition in early HD is neuropsychologically and anatomically generic.

    Neuropsychologia. 2008;46(8):2152-60.
  72. Wild EJ, Mudanohwo EE, Sweeney MG, Schneider SA, Beck J, Bhatia KP, Rossor MN, Davis MB, Tabrizi SJ.
    Huntington’s disease phenocopies are clinically and genetically heterogeneous.

    Mov Disord. 2008 Apr 15;23(5):716-20.
  73. Wild EJ, Tabrizi SJ.
    Biomarkers for Huntington’s disease.

    Expert Opin Med Diagn. 2008 Jan;2(1):47-62.
  74. Bentley P, Qadri F, Wild EJ, Hirsch NP, Howard RS.
    Vasculitic presentation of staphylococcal meningitis.

    Arch Neurol. 2007 Dec;64(12):1788-9.
  75. Wild EJ, Tabrizi SJ.
    The differential diagnosis of chorea.

    Pract Neurol. 2007 Nov;7(6):360-73.
  76. Wild EJ, Tabrizi SJ.
    Huntington’s disease phenocopy syndromes.

    Curr Opin Neurol. 2007 Dec;20(6):681-7.
  77. Runne H, Kuhn A, Wild EJ, Pratyaksha W, Kristiansen M, Isaacs JD, Régulier E, Delorenzi M, Tabrizi SJ, Luthi-Carter R.
    Analysis of potential transcriptomic biomarkers for Huntington’s disease in peripheral blood.

    Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14424-9.
  78. Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Björkqvist M, Petersén A, Jackson GS, Isaacs JD, Kristiansen M, Bates GP, Leavitt BR, Keir G, Ward M, Tabrizi SJ.
    Proteomic profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates.

    J Proteome Res. 2007 Jul;6(7):2833-40.
  79. Wild EJ, Petzold A, Keir G, Tabrizi SJ.
    Plasma neurofilament heavy chain levels in Huntington’s disease.

    Neurosci Lett. 2007 May 7;417(3):231-3.
  80. Wild EJ, Tabrizi SJ.
    Predict-HD and the future of therapeutic trials.

    Lancet Neurol. 2006 Sep;5(9):724-5.
  81. Wild E.
    Deja vu in neurology.

    J Neurol. 2005 Jan;252(1):1-7.
  82. Wild E.
    Thyrotoxic periodic paralysis in a Maori patient.

    N Z Med J. 2004 Dec 17;117(1207):U1204.
  83. Wild E, Gull S.
    Uterine diverticulum as a late complication of caesarean section.

    J Obstet Gynaecol. 2003 Jan;23(1):88.